The Novel TORC1/2 Kinase Inhibitor PQR620 Has Anti-Tumor Activity in Lymphomas as a Single Agent and in Combination with Venetoclax

The Novel TORC1/2 Kinase Inhibitor PQR620 Has Anti-Tumor Activity in Lymphomas as a Single Agent and in Combination with Venetoclax

The phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) signaling cascade is an important therapeutic target for lymphomas. Rapamycin-derivates as allosteric mTOR complex 1 (TORC1) inhibitors have shown moderate preclinical and clinical anti-lymphoma activity. Here, we asse...

Full description

Bibliographic Details
Main Authors: Chiara Tarantelli, Eugenio Gaudio, Petra Hillmann, Filippo Spriano, Giulio Sartori, Luca Aresu, Luciano Cascione, Denise Rageot, Ivo Kwee, Florent Beaufils, Emanuele Zucca, Anastasios Stathis, Matthias P. Wymann, Vladimir Cmiljanovic, Doriano Fabbro, Francesco Bertoni
Format: Article
Language:English
Published: MDPI AG 2019-06-01
Series:Cancers
Subjects:
lymphoma
mTORC1
mTORC2
venetoclax
mantle cell lymphoma
diffuse large B cell lymphoma
Online Access:https://www.mdpi.com/2072-6694/11/6/775

Internet

https://www.mdpi.com/2072-6694/11/6/775

Similar Items